Programa de Respuesta Optimizada para Necesidades de Tratamiento Oportuno en Insuficiencia Cardíaca (PRONTO – IC): Una visión integradora del paciente vulnerable con Insuficiencia Cardíaca
DOI:
https://doi.org/10.63600/an7vdk08Palabras clave:
Insuficiencia cardíaca, Programa, DisneaResumen
La insuficiencia cardíaca (IC) es una enfermedad de alta prevalencia y morbimortalidad, con creciente impacto en los sistemas de salud. El Programa de Respuesta Optimizada para Necesidades de Tratamiento Oportuno en Insuficiencia Cardíaca(PRONTO – IC), impulsado por el Comité de Insuficiencia Cardíaca e Hipertensión Pulmonar de la Federación Argentina de Cardiología, propone un modelo estructurado, personalizado y basado en evidencia, que permite intervenir en momentos críticos de la trayectoria clínica del paciente. El programa aborda cinco escenarios: disnea de nuevo inicio (Clínica de Disnea), descompensación en emergencias, mayor riesgo de rehospitalización (Hospital de Día), pre-shock cardiogénico y período de transición postinternación. Para cada uno,se definen estrategias diagnósticas y terapéuticas específicas, con enfoque multidisciplinario y herramientas de seguimiento, que incluyen desde la evaluación etiológica hasta la optimización farmacológica y la educación del paciente. PRONTO – IC busca mejorar los resultados clínicos mediante una atención proactiva, coordinada y centrada en el paciente.
Referencias
1. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;119(17):2883–2897. doi:10.1093/cvr/cvad098. PMID: 37070334
2. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: The Global Burden of Disease 2010 Study. Circulation.2014;129(14):1493–1501. doi:10.1161/CIRCULATIONAHA.113.004046. PMID: 24573351
3. Thierer J, Perna ER, Marino J, et al. Epidemiología hospitalaria de la insuficiencia cardíaca en la Argentina: Registro OFF-IC. Rev Fed Arg Cardiol. 2022;51(1):37–44. Disponible en: www.revistafac.org.ar
4. Pratter MR, Curley FJ, Dubois J, et al. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med. 1989;149(10):2277–2282.
5. Sahebjami H. Dyspnea in obese healthy men. Chest. 1998;114(5):1373–1377.
6. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205–1211.
7. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452. doi:10.1164/rccm.201111-2042ST. PMID: 22336677; PMCID: PMC5448624.
8. Verwerft J, Soens L, Wynants J, et al. Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic. Eur Heart J. 2023;44(17):1544–1556. doi:10.1093/eurheartj/ehad141
9. Budhwar N, Syed Z. Chronic Dyspnea: Diagnosis and Evaluation. Am Fam Physician 2020;101(9):542-548.
10. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37(27):2129-2200.
11. Fletcher CM, Elmes PC, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2(5147):257-266.
12. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137(3):674–691. doi:10.1378/chest.09-1543. PMID: 20202946; PMCID: PMC3426742.
13. Nazerian P, Vanni S, Volpicelli G, et al. Diagnostic accuracy of emergency Doppler echocardiography for identification of acute left ventricular heart failure in patients with acute dyspnea. Acad Emerg Med 2010;17(1):18–26.
14. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618–3731..
15. Wahls SA. Causes and evaluation of chronic dyspnea. Am Fam Physician 2012;86(2):173-182.
16. Ryan JJ, Waxman AB. The Dyspnea Clinic. Circulation 2018;137(19):1994-1996.
17. Gochicoa-Rangel L, Mora-Romero U, Guerrero-Zúñiga S, et al. Prueba de caminata de 6 minutos: recomendaciones y procedimientos. Neumol Cir Torax. 2015;74(2):127-136. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S002837462015000200008&lng=es
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166(1):111-117.
19. Zielińska D, Bellwon J, Rynkiewicz A, et al. Prognostic Value of the Six-Minute Walk Test in Heart Failure Patients Undergoing Cardiac Surgery: A Literature Review. Rehabil Res Pract 2013;2013:1-5.
20. Nuraj V, Iwona C, Mintu T, et al. Declaración Conjunta 2020 de la ISHNE/HRS/EHRA/APHRS sobre el manejo de Arritmias mediante mHealth. Rev Argent Cardiol 2020;88(6):550-578.
21. Sevilla Ruiz T, Arnold R, Amado M, et al. Técnicas de imagen no invasivas en la investigación cardiovascular. Rev Esp Cardiol Supl 2013;13(E):64-72.
22. Shah SJ, Cogswell R, Ryan JJ, et al. How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. Curr Cardiol Rep 2016;18(12):122.
23. Nasca PF, et al. Manejo de pacientes con insuficiencia cardiaca con fracción de eyección preservada. Rev Fed Arg Cardiol 2024;53(Supl 2):3-21.
24. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020;141:139-596.
25. Reddy YNV, Carter RE, Obokata M, et al. Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 2018;138(9):861-870.
26. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA‐PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:391-412.
27. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40(40):3297-3317.
28. Buber J, Robertson HT. Cardiopulmonary exercise testing for heart failure: pathophysiology and predictive markers. Heart 2023;109:256-263.
29. Iglesias D, Dávolos I, Franchella J, Arce S, Filosa E, González Y, et al. Guías Argentinas intersocietarias de prueba de ejercicio cardiopulmonar. Rev Argent Cardiol. 2025;93(Supl 8):1-116. https://doi.org/10.7775/rac.es.v93.s8
30. Maron BA, Cockrill BA, Waxman AB, et al. The invasive cardiopulmonary exercise test. Circulation 2013;127:1157-1164.
31. Del Rio-Pertuz G, Nugent K, Argueta-Sosa E. Right heart catheterization in clinical practice: a review of basic physiology and important issues relevant to interpretation. Am J Cardiovasc Dis **2023**;13(3):122-137.
32. Coronel L, Diez M, Lema LR, et al. Recomendaciones para la realización de cateterismo cardíaco derecho en hipertensión pulmonar: Documento conjunto de la Federación Argentina de Cardiología y la Sociedad Argentina de Cardiología. Rev Fed Arg Cardiol [revista electrónica] 2022; 51:4-22. Disponible en: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/414
33. Ewert R, Heine A, Müller-Heinrich A, et al. Exercise and fluid challenge during right heart catheterisation for evaluation of dyspnoea. Pulm Circ 2020;10(3):2045894020917887.
34. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail 2021;23(3):352-380.
35. Storrow AB, Jenkins CA, Self WH, et al. The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail 2014;2(3):269-277.
36. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008;168(8):847-854.
37. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2022;24:4-131.
38. Kitai T, Kohsaka S, Kato T, et al. JCS/JHFS 2025 guideline on diagnosis and treatment of heart failure. J Card Fail. 2025. doi:10.1016/j.cardfail.2025.02.014.
39. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev 2007;12:87-90.
40. De la Espriella R, Cobo M, Santas E, et al. Evaluación de las presiones de llenado y la sobrecarga de volumen en la insuficiencia cardiaca: una visión actualizada. Rev Esp Cardiol 2023;76:47-57.
41. Fudim M, Hernandez AF, Felker GM, et al. Role of Volume Redistribution in the Congestion of Heart Failure. J Am Heart Assoc 2017;6:e006817.
42. Nuñez CR, Manfredi CE, Cerri E, et al. Guía práctica del Comité de Insuficiencia Cardíaca e Hipertensión Pulmonar de la Federación Argentina de Cardiología para el manejo de la congestión en pacientes con insuficiencia cardíaca. Rev Fed Arg Cardiol [revista electrónica] 2025;54:3-18. Disponible en: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/675
43. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2010;12:423-433.
44. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137-155.
45. Kuo DC, Peacock WF. Diagnosing and managing acute heart failure in the emergency department. Clin Exp Emerg Med 2015;2(3):141-149.
46. Hunter BR, Martindale J, Abdel-Hafez O, et al. Approach to acute heart failure in the emergency department. Prog Cardiovasc Dis 2017;60(2):178-186.
47. Goldberg RJ, Spencer FA, Szklo-Coxe M, et al. Symptom presentation in patients hospitalized with acute heart failure. Clin Cardiol 2010;33:E73-80.
48. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-88.
49. Boorsma EM, Ter Maaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis, and treatment. Nat Rev Cardiol 2020;17:641-55.
50. Peacock WF, Braunwald E, Abraham W, et al. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol 2010;56(5):343-51.
51. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance of the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715-31.
52. Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev 2014;19(4):421-38.
53. Pellicori P, Platz E, Dauw J, et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail 2021;23:703-12.
54. Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail 2019;21:904-16.
55. Platz E, Campbell RT, Claggett B, et al. Lung Ultrasound in Acute Heart Failure. JACC Heart Fail 2019;7:849-58.
56. Rivas-Lasarte M, Álvarez-García J, Fernández-Martínez J, et al. Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study). Eur J Heart Fail 2019;21:1605-13.
57. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
58. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17(6):544–558. doi:10.1002/ejhf.289. PMID: 25903734.
59. Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol 2018;3(3):252-59.
60. Comín-Colet J, Enjuanes C, Verdú-Rotellar JM, et al. Utility of a heart failure day hospital unit for the prevention of hospital admissions: analysis of 2500 consecutive visits. Rev Esp Cardiol (Engl Ed) 2014;67(12):1010-19.
61. Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy. JAMA Cardiol 2018;3(3):252-59.
62. Abbo A, Gruber A, Volis I, et al. Eficacia de la diuresis en pacientes ambulatorios con insuficiencia cardíaca congestionada: comparación intrapaciente de 3 regímenes diuréticos (DEA-HF). J Am Coll Cardiol HF 2024;12(8):1396-1405.
63. Orozco Burbano JD, Saldarriaga Giraldo CI, Echeverri Marín DA. Hypertonic saline solution and high dose of diuretic, what do we know and how can we use them in persistent congestion? Arch Peru Cardiol Cir Cardiovasc 2021;2(4):247-53.
64. Cobo Marcos M, de la Espriella R, Comín-Colet J, et al. Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: the SALT-HF trial. Eur J Heart Fail 2024;2118-28.
65. Noutary F, Swieszkowski S. Ciclos ambulatorios y repetitivos de levosimendán en insuficiencia cardíaca avanzada. Rev Argent Cardioangiol Interv 2021;12(2):74-81.
66. Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 2014;16(8):898-906.
67. Comín-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20(7):1128-1136.
68. García-González MJ, Aldea Perona A, Lara Padron A, et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC Heart Fail. 2021;8:4820-4831.
69. Dobarro D, Donoso-Trenado V, Solé-González E, et al. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC Heart Fail. 2023;10:1193-1204.
70. Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18:798-802.
71. Masini G, Graham FJ, Pellicori P, et al. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol. 2022;79:341-351.
72. Anker SD, Khan MS, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis. Eur J Heart Fail. 2023;25(7):1080-1090.
73. Graham FJ, Pellicori P, Kalra PR, et al. Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail. 2023;25(4):528-537.
74. Moris C, Lescano A, Nasca P, et al. Recomendaciones conjuntas de la Federación Argentina de Cardiología y la Sociedad Argentina de Cardiología sobre diagnóstico y tratamiento del déficit de hierro en la insuficiencia cardíaca. Rev. Fed. Arg. Cardiol. 2023;52:7-24. Disponible en: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/534
75. Sinha SS, Morrow DA, Kapur NK, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock. J Am Coll Cardiol. 2025;S0735-1097(25)00418-8.
76. Van Diepen S, Katz J, Albert N, et al. Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation. 2017;136:e232-e268.
77. Castillo Costa Y, Garcia Aurelio M, Mauro V, et al. Registro Nacional Argentino de Shock Cardiogénico (ReNa-SHOCK). Rev Argent Cardiol. 2016;84:228-235.
78. Castillo Costa Y, Delfino F, Mauro V, et al. Shock cardiogénico en el contexto de los síndromes coronarios agudos en Argentina: resultados del Registro ARGEN SHOCK 2. Rev Argent Cardiol. 2023;91:251-256.
79. Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419-2432.
80. Thiele H, Zeymer U, Akin I, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389(14):1286-1297.
81. Cacciatore F, Costabel JP, Sanmartino J, et al. Consenso de expertos de la Sociedad Argentina de Cardiología sobre diagnóstico y tratamiento del shock cardiogénico. Rev Argent Cardiol. 2024;92(3):1–27.
82. Waksman R, Pahuja M, van Diepen S, et al. Standardized definitions for cardiogenic shock research and mechanical circulatory support devices: scientific expert panel from the Shock Academic Research Consortium (SHARC). Circulation. 2023;148:1113-1126.
83. Kapur NK, Kanwar M, Sinha SS, et al. Criteria for defining stages of cardiogenic shock severity. J Am Coll Cardiol. 2022;80(3):185-198.
84. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheter Cardiovasc Interv. 2019;94(1):29-37.
85. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies. J Soc Cardiovasc Angiogr Interv. 2022;79(9):933-946.
86. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1990;66(19):1348-1354.
87. Ranka S, Mastoris I, Kapur NK, et al. Right heart catheterization in cardiogenic shock is associated with improved outcomes: insights from the nationwide readmissions database. J Am Heart Assoc. 2021;10(17):e019843.
88. Kadosh BS, Berg DD, Bohula EA, et al. Pulmonary artery catheter use and mortality in the cardiac intensive care unit. JACC Heart Fail. 2023;11(8 Pt 1):903–14. doi:10.1016/j.jchf.2023.04.007.
89. Celso B, Tepas J, Langland-Orban B, et al. A systematic review and meta-analysis comparing outcome of severely injured patients treated in trauma centers following the establishment of trauma systems. J Trauma. 2006;60(2):371–8. doi:10.1097/01.ta.0000197916.99629.eb.
90. Ju T, Al-Mashat M, Rivas L, Sarani B. Sepsis rapid response teams. Crit Care Clin. 2018;34(2):253–8. doi:10.1016/j.ccc.2017.12.004.
91. Jaroszewski DE, Kleisli T, Staley L, et al. A traveling team concept to expedite the transfer and management of unstable patients in cardiopulmonary shock. J Heart Lung Transplant. 2011;30(6):618–23. doi:10.1016/j.healun.2010.11.018.
92. Doll JA, Ohman EM, Patel MR, et al. A team-based approach to patients in cardiogenic shock. Catheter Cardiovasc Interv. 2016;88(3):424–33. doi:10.1002/ccd.26297.
93. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063.
94. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74(15):1966–2011. doi:10.1016/j.jacc.2019.08.001. PMID: 31526538.
95. Hollenberg SM, Stevenson LW, Ahmad T, et al. 2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;84(13):1241–1267. doi:10.1016/j.jacc.2024.06.002. PMID: 39127954.
96. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34:835–43.
97. Lobo Marquez L. Congestión y su diagnóstico en la insuficiencia cardíaca crónica descompensada. Insuf Card. 2020;15(4):106–118.
98. Gheorghiade M, Vaduganathan M, Fonarow G, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.
99. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation. 2003;108:1945–53.
100. Seghatol FF, Shah DJ, Diluzio S, et al. Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2004;93:854–9.
101. Kittleson M, Panjrath G, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2023;81(18):1835–78.
102. Cannata A, McDonagh T. Heart failure with preserved ejection fraction. N Engl J Med. 2025;392:173–84. doi:10.1056/NEJMcp2305181.
103. Lindberg F, Savarese G. Worsening heart failure: an opportunity for treatment implementation even with a preserved ejection fraction? J Am Coll Cardiol. 2024. doi:10.1016/j.jacc.2024.09.022.
104. Biegus J, Moayedi Y, Saldarriaga C, Ponikowski P. Getting ahead of the game: in-hospital initiation of HFrEF therapies. Eur Heart J Suppl. 2022;24(Suppl L):L38–L44. doi:10.1093/eurheartjsupp/suac120.
105. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, et al. Safety, tolerability, and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised trial. Lancet. 2022;400(10367):1938–52. doi:10.1016/S0140-6736(22)02076-1.
106. Diez M, Perna ER, Fairman E, et al. Recomendaciones conjuntas de la Sociedad Argentina de Cardiología y la Federación Argentina de Cardiología para el manejo de la insuficiencia cardíaca. Uso de nuevas drogas antidiabéticas en insuficiencia cardíaca. Rev Fed Arg Cardiol. 2020;49(Supl):1–66.
107. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568–74.
108. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48. doi:10.1056/NEJMoa1812851. PMID: 30415601.
109. Perna ER, Diez M, Borracci RA, et al. Recomendaciones conjuntas de la Sociedad Argentina de Cardiología y la Federación Argentina de Cardiología para el manejo de la insuficiencia cardíaca. Rol de los inhibidores del receptor de angiotensina y neprilisina (ARNi). Rev Fed Arg Cardiol. 2021;50(Supl 1):1–34.
110. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998–1007.
111. Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139(19):2285–2288. doi: 10.1161/CIRCULATIONAHA.118.039331.
112. Armstrong PW, Roessig L, Patel MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail. 2018;6(2):96–104. doi: 10.1016/j.jchf.2017.08.013.
113. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885.
114. Desai AS, Vaduganathan M, Claggett BL, et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025;85(2):106-116. doi: 10.1016/j.jacc.2024.09.004.
115. Fairman E, Echazarreta D, Fernandez A, et al. Recomendaciones Conjuntas de la Federación Argentina de Cardiología y la Sociedad Argentina de Cardiología para el uso de Antagonistas de los Receptores de Mineralocorticoides en la Insuficiencia Cardíaca. Integrando a la Finerenona. Rev. Fed. Arg. Cardiol. [Internet]. 2025 Jun. 9 [cited 2025 Jul. 5];54:3-17. Disponible en: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/712
116. Vaduganathan M, Claggett L, Kulac I, et al. Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation. 2024;149(13):964–976. doi:10.1161/CIRCULATIONAHA.123.065347.
117. Comín-Colet J, Enjuanes C, Lupón J, et al. Transitions of care between acute and chronic heart failure: critical steps in the design of a multidisciplinary care model for the prevention of rehospitalization. Rev Esp Cardiol. 2016;69(10):951–961.
118. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120(12):1141–1163. doi: 10.1161/CIRCULATIONAHA.109.192628.
119. Spahillari A, Cohen LP, Lin C, et al. Efficacy, safety and mechanistic impact of a heart failure guideline-directed medical therapy clinic. JACC Heart Fail. 2024;Oct 9. [Epub ahead of print]. doi: 10.1016/j.jchf.2024.08.017.
120. Poggio R, Ortiz LM, Rivadulla N, et al. A heart failure program in low-income patients in Argentina (COMM-HF). Arch Peru Cardiol Cir Cardiovasc. 2024;5(4):215–225. doi: 10.47487/apcyccv.v5i4.432.
